Production

Manufacturing Facilities

The Company has 10.22 acres of land near Muppireddy Palli Village, Manoharabad Mandal, Medak Dist. in the Southern State of Telangana, India. The land is totally developed, and the facility has all the utilities sufficient for existing and future requirements. The facility was established after obtaining all the required approvals from Government Authorities.

The company’s manufacturing equipment enables the production of various types of patches. Quality Control can analyze pharmaceutical raw materials as well as finished transdermal products. The company has 20,000 Sq. Ft. of space reserved for GMP production facilities with space available for future growth. The production facility currently has 14,000 Sq. Ft. of production area and 3,000 Sq. Ft. of Quality Control laboratory.

The existing facility has a capacity of manufacturing 10-15 million units patches in a shift.

production

Production Plant

Survey No. 354, Muppireddypally Village, Manoharabad (Mandal), Medak District - 502336 Telangana State, India.

image here

Quality Policy

Our mission at Sparsha Pharma is to develop clinically effective, innovative and affordable Transdermal therapeutic products to improve the quality of life of patients in need of such therapies.

Sparsha Pharma products are to meet international standards of quality.

We, as a Team, dedicate ourselves to achieve this objective by maintaining quality every stage and by complying with all current regulatory requirements.

Unique Specifications of Sparsha Pharma International Private Limited

With a cumulative experience of over 30 years among our R&D staff and over 16 years of specialized involvement in matrix technology development, Sparsha Pharma International Private Limited stands as the single Indian company with a robust foothold in the transdermal technology market. Our track record includes an annual supply of over 10 million patches to both domestic and international markets, solidifying our position as a leader in this field.

As adhesion is the key for transdermal technology maintaining adhesion in topical countries like India is not everyone’s cup of tea but we Sparsha Pharma International Private Limited made these happened

Product Areas

  • Transdermal Products
  • Pain related Transdermal Patches
  • Narcotic Patches
  • Cosmetics Patches

Fentanyl Transdermal Patch (Fen-Touch/ Fen-Spar)

Fentanyl Transdermal Patches is indicated in the management of chronic intractable...

Read More

Diclofenac Transdermal patch (D-Touch)

Diclofenac Diethylamine B.P. 100 mg Transdermal Patch, for the relief of pain and inflammation...

Read More

Rivastigmine Transdermal Patch (RivaSpar)

Rivastigmine Transdermal Patches has just been launched in December 2012 for Alzheimer’s...

Read More

Buprenorphine Transdermal Patch (Bue Touch/ BueSpar)

Buprenorphine Transdermal Patches indicated in the management of moderate...

Read More

Lidocaine Patch 5% (Lido-Touch)

The Lidocaine patch 5% exhibit efficacy to treat pain related to post-herpetic neuralgia and is effective...

Read More

Nicotine Transdermal Patch (Nico-Touch)

NicoTouch patch is designed to help people quit smoking using the principle of nicotine...

Read More

Tulobuterol Transdermal Patch (Tulo-Touch)

Tulobuterol transdermal patch is a square system consisting of a release liner, drug in adhesive...

Read More